Here's What Investors Should Know About Johnson & Johnson's FDA Authorization
In this video from Motley Fool Live, recorded on March 1, Fool.com Contributors Brian Orelli and Keith Speights discuss the FDA's emergency use authorization (EUA) for Johnson & Johnson's (NYSE: JNJ) coronavirus vaccine. The duo talk about the advisory committee meeting that reviewed the merits of the authorization, as well as the lack of information on the vaccine's use in older adults.
Source Fool.com